Research Study

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's
Principal Investigator 
Ging-Yuek Robin Hsiung

Overview

Body Locations and Systems 
Alzheimer's Disease
Disorders and Conditions 
Alzheimer's Disease
ClinicalTrials.gov# 
NCT02477800
Status 
Recruiting
Study Start/End 
Jan 8, 2016 to Oct 1, 2017
Locations 
UBC Hospital
Name/Title 
Eloise Nicklin, Research Coordinator
Phone 
604-822-0324
Email Address 
eloise.nicklin@vch.ca
Purpose of Study 

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale (13 items) [ADAS-Cog 13], and AD Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) [ADCS-ADL-MCI].
 

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.